Q-omics provides the consensus-scored EBPL profile across patient tissues and cancer cell-line models. EBPL expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, EBPL is differentially expressed in 12, with the highest sampling consensus in COAD. Additionally, EBPL RNA expression shows 17,780 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight KIRP, COAD, and ACC as cancer lineages where EBPL shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for EBPL — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes EBPL survival associations across molecular data types. EBPL RNA expression shows survival associations in the most cancer types (25), followed by mutation status (4) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible EBPL RNA expression–survival associations across cancer types. High EBPL expression shows unfavorable associations in KIRP, CESC, UVM, HNSC, LUAD and ACC. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for EBPL RNA expression.
This table summarizes EBPL tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for EBPL. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. EBPL shows higher tumor expression in COAD, KIRC, STAD, BLCA, KIRP and READ. The COAD box plot shows higher EBPL RNA expression in tumor versus normal tissue (log2 FC = +1.293, t-test p < 0.001).
This table shows molecular features associated with EBPL in patient tissues and cancer cell lines. In patient samples, EBPL shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, EBPL RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BREAST, while CRISPR and shRNA rows add functional-dependency signals in SOFT_TISSUE and BLOOD_Leukemia.
